NicOx partner Topigen starts phase 2 respiratory disorder program

By Elaine Rigoli

Tampa, Fla., May 23 - NicOx SA's partner, Topigen Pharmaceuticals, Inc., has started a phase 2 development program for TPI-1020 (formerly NCX 1020) in respiratory disorders.

Topigen aims to develop TPI-1020 as a treatment for chronic obstructive pulmonary disease, which could be more effective than conventional corticosteroids, according to a company news release.

TPI-1020 is a novel, inhaled, nitric oxide-donating derivative of budesonide, for which Topigen licensed North American rights and an option on worldwide rights from NicOx in 2005, the release said.

The first phase 2 clinical trial started by Topigen has the primary objective of assessing the general safety, tolerability and pharmacodynamic activity of inhaled TPI-1020 in smokers with asthma and is expected to be followed by a subsequent trial in chronic obstructive pulmonary disease.

NicOx is a product-driven biopharmaceutical company based in Sophia-Antipolis, France.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.